EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report

Jenny L Wu, Wade T Iams

Oncotarget · 2025

DOI: 10.18632/oncotarget.28682 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Oncotarget, 2025. Verfasst von Jenny L Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Hauptthemen laut MEDLINE: Antigens, Differentiation, B-Lymphocyte, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Gene Rearrangement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, Differentiation, B-LymphocyteCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmGene RearrangementLactams, MacrocyclicLung NeoplasmsOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-retRetinoblastoma Binding ProteinsHumansAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsLactamsPyrazolesHistocompatibility Antigens Class II

Stichwörter der Autor:innen

RET rearrangementROS1 rearrangementcase reportnon-small cell lung cancertargeted therapy

Substanzen

AminopyridinesAntigens, Differentiation, B-Lymphocyteinvariant chainLactamsLactams, MacrocycliclorlatinibOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-ret

Autor:innen und Institutionen

  • Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
  • Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA.

Zitieren

APA

Wu, J. L., & Iams, W. T. (2025). Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report. Oncotarget. https://doi.org/10.18632/oncotarget.28682

Vancouver

Wu JL, Iams WT. Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report. Oncotarget. 2025. doi:10.18632/oncotarget.28682

BibTeX
@article{Wu2025,
  author = {Wu, Jenny L and Iams, Wade T},
  title = {Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report},
  journal = {Oncotarget},
  year = {2025},
  doi = {10.18632/oncotarget.28682}
}
Kostenlos starten →